Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.
Press Enter ↵ to search evidence
Explore by Goal
"Imagination is more important than knowledge. Knowledge is limited. Imagination encircles the world."
A 2025 living systematic review/meta-analysis pooled HLA-B*58:01 prevalence in SCAR cases = 88.5% (95% CI 81.3–93.1) and allopurinol-tolerant controls = 10.5% (95% CI 8.8–12.4), with a pooled OR = 117.6 (95% CI 70.3–196.8) for association with allopurinol-induced SCARs.
Key nuance: in some cohorts, HLA-B*58:01 is an incomplete predictor and may require additional genetic/clinical context.
Primary sources: living meta-analysis and mechanistic/contrast studies cited below.
Long Explanation
Meta-analysis snapshot: HLA-B*58:01 and allopurinol-induced SCAR
The central, quantitative claim from the provided evidence is that HLA-B*58:01 is strongly enriched in allopurinol-induced severe cutaneous adverse reactions (SCARs), with an extremely high pooled odds ratio—but also with meaningful heterogeneity and observed incomplete prediction in at least some non-Asian/non-uniform datasets.
Known (from meta-analysis):
HLA-B*58:01 prevalence in SCAR cases pooled to 88.5% (95% CI 81.3–93.1; I²=80%); prevalence in allopurinol-tolerant controls pooled to 10.5% (95% CI 8.8–12.4; I²=53%); and pooled association OR=117.6 (95% CI 70.3–196.8; I²=45%).
Uncertain / caveats (from provided contrast studies):
A 2025 analysis in a primarily self-identified Black US cohort (16 allopurinol-SCAR cases, 1,122 controls) reports HLA-B*58:01 present in 62.5% of cases, concluding it is an incomplete predictor; it also identifies HLA-A*34:02 as an additional risk factor in that dataset.
Data and uncertainty intervals are taken directly from the provided living meta-analysis pooling results.
The OR and 95% CI are pooled from 24 case-control studies with reported heterogeneity (I²=45%) and possible publication bias (Egger’s test P<0.001) in the living meta-analysis.
Subgroup prevalence estimates are reported as ~91.1% (Asia) vs ~60.3% (White Europe) for SCAR cases in the living meta-analysis summary provided.
A critical reality check: “strong association” ≠ “complete prediction”
A 2025 cohort study in a US population (primarily self-identified Black) found HLA-B*58:01 in 62.5% of allopurinol-SCAR cases (16 cases total), and reports that HLA-B*58:01 alone is an incomplete predictor; it adds HLA-A*34:02 as an additional risk factor in that dataset.
This pie chart uses the provided cohort summary value (62.5% with HLA-B*58:01 among 16 SCAR cases).
Evidence table (from the provided extracts)
Use this to quickly compare pooled estimates vs single-cohort contrast.
Beyond epidemiologic association, the provided dataset includes an in-vitro structural/biophysical study showing that allopurinol can facilitate stable binding of unconventional peptides to recombinant HLA-B*58:01, with crystallographic and thermal-stability observations that support a noncovalent, pharmacologic-interaction-like mechanism.
These Tm values come from the provided in vitro study excerpt’s thermal-stability table for specific peptide examples.
What would change the conclusion (falsification targets)
If future large, well-controlled prospective studies in diverse ancestries found that HLA-B*58:01 carriers do not have substantially elevated allopurinol-SCAR risk (OR near 1 with tight CIs), that would weaken the causal inference from association studies.
If additional mechanistic work failed to support the drug-facilitated peptide loading model (or showed it is irrelevant in vivo), the plausibility link between allopurinol, HLA-B*58:01, and SCAR pathogenesis would be undermined.
It ingests the provided pooled prevalence/OR values to generate Plotly visuals and a searchable evidence table, then reconciles meta-analysis vs contrast cohort discrepancies into a single comparative dashboard.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“HLA-B*58:01 fully explains allopurinol-SCAR across ancestries.” This is weakened by the provided cohort where only 62.5% of cases carried HLA-B*58:01 and the authors explicitly call it incomplete.
“Allopurinol’s structural effect on HLA-B*58:01 is the only relevant mechanism.” In vitro peptide-loading limitations and dataset heterogeneity imply other genetic/immune context factors likely contribute.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
Keep Exploring
